Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis

Shijia Zhang, Amit A. Kulkarni, Beibei Xu, Haitao Chu, Taxiarchis Kourelis, Ronald S. Go, Michael L. Wang, Veronika Bachanova, Yucai Wang

Research output: Contribution to journalArticle

Abstract

Bortezomib-based regimens are widely used as induction therapy for multiple myeloma (MM). Unlike lenalidomide, the role of bortezomib in consolidation and maintenance therapy for MM is less clear. We performed a meta-analysis to evaluate the impact of bortezomib-based consolidation and maintenance therapy on survival outcomes and adverse events. PubMed, Web of Science, Embase databases, and major conference proceedings were searched for randomized controlled trials (RCTs) of bortezomib-based regimens as consolidation or maintenance therapy for MM. Ten RCTs enrolling 3147 patients were included in the meta-analysis. Bortezomib-based regimens were compared with regimens without bortezomib or observation. The meta-analysis suggested that bortezomib-based maintenance therapy improved progression-free survival (PFS; hazard ratio [HR] = 0.72, 95% CI 0.55–0.95, P = 0.02) and overall survival (OS; HR = 0.71, 95% CI 0.58–0.87, P = 0.001). Bortezomib-based consolidation therapy improved PFS (HR = 0.77, 95% CI 0.68–0.88, P < 0.001) but not OS (HR = 0.98, 95% CI 0.78–1.24, P = 0.87). Bortezomib-based consolidation/maintenance therapy led to a trend toward increased risk of grade ≥ 3 neurologic symptoms, gastrointestinal symptoms, and fatigue. More research is warranted to further assess the role of bortezomib-based consolidation and maintenance therapy for multiple myeloma.

Original languageEnglish (US)
Article number33
JournalBlood cancer journal
Volume10
Issue number3
DOIs
StatePublished - Mar 1 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis'. Together they form a unique fingerprint.

  • Cite this

    Zhang, S., Kulkarni, A. A., Xu, B., Chu, H., Kourelis, T., Go, R. S., Wang, M. L., Bachanova, V., & Wang, Y. (2020). Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood cancer journal, 10(3), [33]. https://doi.org/10.1038/s41408-020-0298-1